Zephyrm rides IPO updraft toward Hong Kong listing, seeking cash for phase 3 cell therapy trials

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing for an IPO to bankroll phase 3 trials of its cell therapy in a lung condition and graft-versus-host disease (GvHD).